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Abstract
The ability to measure biochemical and molecular processes under-
lies progress in breast cancer biology and treatment. These assays
have traditionally been performed by analysis of cell culture or tissue
samples. More recently, functional and molecular imaging has
allowed the in vivo assay of biochemistry and molecular biology,
which is highly complementary to tissue-based assays. This review
briefly describes different imaging modalities used in molecular
imaging and then reviews applications of molecular imaging to
breast cancer, with a focus on translational work. It includes
sections describing work in functional and physiological tumor
imaging, imaging gene product expression, imaging the tumor
microenvironment, reporter gene imaging, and cell labeling. Work in
both animal models and human is discussed with an eye towards
studies that have relevance to breast cancer treatment in patients.
Introduction
The ability to assay cancer biological features is key to
advances in both the basic and clinical science of breast
cancer. Advances in our ability to assay molecular processes,
including gene expression, protein expression, and molecular
and cellular biochemistry, have fueled recent advances in our
understanding of breast cancer biology and our ability to treat
breast cancer in patients. Most assays require sampling of
cells or tissues to perform the measurements. Thus, the cell
culture system, animal model, or patient must be perturbed in
order to perform the assay. This requirement makes serial
assays over time more difficult and leaves open the possibility
that the assay itself may change the state of the system being
measured. The ability to measure biological processes
without perturbing them would be highly desirable and would
offer complementary information to that obtained by most
traditional assay methods.
Advances in both technology and cancer science have led to
the ability to perform non-invasive molecular assays. An
example is the use of reporter genes whose expression
results in the production of material such as green
fluorescent protein or luciferase that can be detected without
tissue sampling [1]. Another advance, applicable to the entire
range of biological systems from cell culture to human, is
molecular imaging [2,3], which is the focus of this review.
Imaging has traditionally relied on structural and anatomic
features to detect breast cancer and determine its extent [4].
This traditional form of imaging, often termed anatomic
imaging, has made an important contribution to cancer care,
and is widely used in the detection and staging of breast
cancer patients using methods such as X-ray mammography
and computed tomography (CT). More recently, imaging has
expanded to include the ability to image regional biochemistry
and molecular biology, often termed molecular imaging [2].
The focus for molecular imaging is not structure, but rather
regional biology. Quantitative analysis is an important feature
of this type of imaging, for example, the ability to measure
regional tumor receptor expression [5,6]. As such, molecular
imaging can be considered an in vivo assay technique,
capable of measuring regional tumor biology without perturb-
ing it. This makes molecular imaging a unique tool for probing
breast cancer biology, complementary to traditional assay
methods, and a potentially very powerful tool for translational
science. In the sections that follow, imaging methods used in
molecular imaging are reviewed, the biological processes that
can be assayed are discussed, and selected examples of
translational science using molecular imaging are reviewed.
The focus is on in vivo imaging of animal models and patients.
It is important to keep in perspective inherent differences in
capabilities between tissue-based assays and in vivo assays
using molecular imaging. Imaging is non-invasive and,
therefore, better suited to serial assay. In addition, imaging
typically surveys the entire animal or patient and, therefore,
avoids sampling errors that can occur for assays that require
tissue sampling, especially when there is significant tumor
heterogeneity. However, while sample-based methods can
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assay many different processes at once - for example, the
expression of an array of genes [7] - imaging can typically
sample at most a few processes at the same time. Also, while
it is possible to ‘batch’ process for many samples at the same
time, imaging needs to be performed one subject at a time.
Furthermore, the need for sophisticated equipment and
imaging probes makes imaging typically more expensive than
sample-based assays. These last two factors limit the number
of subjects that can be studied by imaging compared to
sample assays. In general, imaging methods are comple-
mentary to assay-based methods and best used to explore
breast cancer biology in intact animal models or patients, or
to image the effects of therapeutic intervention on in vivo
tumor biology.
Imaging modalities
The imaging modalities most commonly used in molecular
imaging are listed in Table 1. Common among these modali-
ties is the ability to image functional and molecular tissue
properties such as perfusion, metabolism, and receptor or
oncogene expression [5,8-12]. This section provides a brief
description of each modality, along with its advantages and
disadvantages.
Magnetic resonance imaging
Magnetic resonance (MR) relies upon the interaction of
atomic nuclei with radiofrequency signals in the presence of
strong magnetic fields. MR imaging (MRI) offers high spatial
resolution and functional contrast agents using magnetic
elements such as Gd and Fe [10]. Breast MRI using non-
specific contrast agents such ad Gd-DTPA has become an
important part of clinical breast cancer [13], and there have
been some notable recent successes in the use of breast
MRI for breast cancer detection [14]. More detailed and
quantitative approaches to dynamic contrast enhanced
(DCE) breast MRI have been increasingly used to examine
tumor perfusion and capillary permeability as an indicator of
tumor angiogenesis [15-17]. More specific and targeted MRI
agents have also been developed and undergone preliminary
testing [18]; however, the range of possible molecular agents
is somewhat constrained by the need to include a
magnetically active atom such as Gd or Fe. Recent advances
in pulse sequences and image acquisition have led to the
ability to measure other tissue properties, such as water
diffusion, that can provide information on cellularity and
interstitial transport without the need for contrast [19,20]. An
advantage of MRI is its high spatial resolution and image
quality, especially with increasing magnetic field strength,
making it applicable to both small animals and patient
imaging. Limitations include the cost of the imaging system
and the thus far somewhat limited range of imaging probes
that serve as MR contrast agents, although new approaches
tested in pre-clinical models will provide increased capabili-
ties for animal research and may be able to be translated to
patient studies [18].
Magnetic resonance spectroscopy
MR spectroscopy (MRS) takes advantage of the ability of
nuclear magnetic resonance to identify specific chemical
signatures and measures the regional concentrations of bio-
Table 1
Functional and molecular imaging methods
Modality Advantages Disadvantages
Magnetic resonance
Magnetic resonance imaging (MRI) High spatial resolution and image detail Confined space
Increasing range of contrast agents under  Contrast design limited by need for magnetic 
development atom
Magnetic resonance spectroscopy (MRS) Can measure wide range of molecules Limited spatial resolution
No contrast needed Challenging to get high quality spectra in routine 
imaging
Radionuclide imaging
Positron emission tomography (PET) Wide range of molecular imaging probes Limited spatial resolution
Tracer imaging without perturbing biological  Some radiation exposure
system
Single photon emission tomography  Similar to PET Less quantitatively accurate than PET
(SPECT) Probes more widely available
Ultrasound, especially with contrast  Highly portable, inexpensive Operator dependence
enhancement Molecular microbubble contrast agents  Contrast agents confined to vascular space thus 
possible far
Optical imaging Highly portable, inexpensive Limited penetration from surface, limited to 
High spatial resolution possible relatively superficial sitesPage 3 of 12
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chemical species, using methods similar to those developed
for basic chemical assays [9]. Much of current work in
patients uses hydrogen spectroscopy; however, spectroscopy
for other biologically relevant nuclei, such as phosphorus or
sodium, is also possible [21]. MRS can quantify the
concentration of prevalent biochemical species without
perturbing the system being imaged, and without the need for
imaging contrast administration. MRS has considerably more
limited spatial resolution compared to MRI; however, recent
advances in magnetic field strength and MRS technology
have yielded the ability to generate three-dimensional MRS
concentration maps (MRS images, MRSI) with resolution on
the order of 1 cm or less [9]. Recent studies suggest that
changes in local metabolites with therapy may provide a very
early indicator of breast cancer response [22]. MRS has the
advantage of being able to directly quantify molecular species
without the need for contrast, with the disadvantages of more
limited spatial resolution and the need for relatively high
abundance to be able to reliably quantify regional bio-
chemical concentration. It shares the need for relatively
expensive equipment with MRI, and in fact, requires fairly high
field strength, typically 3T or more, to be effective for animal
and patient breast studies [9].
Radionuclide imaging
Radionuclide imaging relies on the use of imaging probes,
typically termed radiopharmaceuticals, tagged with radio-
active nuclei [5]. Position-sensitive radiation detectors identify
emitted photons and generate images of regional
radiopharmaceutical concentration. This imaging approach,
sometimes called nuclear medicine, has traditionally relied on
gamma-emitters such as 99mTc or 131I to form images in a
technique often termed single-photon computed tomography
(SPECT)). Somewhat more recently, advances in both
instrumentation and radiochemistry have led to the ability to
image positron-emitting nuclei, such as 11C and 18F, in a wide
range of molecules in an approach known as positron
emission tomography (PET) [23]. Compared to SPECT, PET
offers the potential for better spatial resolution, more accurate
image quantification, and a wider range of possible imaging
probes; however, both PET and SPECT have made notable
contributions to breast cancer clinical care and research
[5,23,24]. The chief advantage of radionuclide imaging is the
ability to measure probe concentrations in the nanomolar, and
even picomolar, range, leading to the ability to measure even
the most sensitive molecular processes without perturbing
them. A wide range of radiopharmaceuticals has been
developed to image diverse aspects of breast cancer biology
[25]. Disadvantages include more limited spatial resolution
and the need to produce and distribute relatively short-lived
imaging probes. Recent development in dedicated imaging
devices for small animals [26] and breast-specific imaging
[27] has overcome some of the limitations in spatial
resolution; however, inherent spatial resolution is less than for
other methods such as CT or MRI. The combination of PET or
SPECT with X-ray CT (PET/CT or SPECT/CT) yields co-
registered molecular and anatomic images and the
opportunity to image molecular biology and anatomy
simultaneously [28]. Radionuclide imaging probes and
instrumentation are relatively expensive, with costs
comparable to MRI.
Optical imaging
One of the oldest forms of imaging is optical imaging, using
visible light to generate images. In many ways optical imaging
is the earliest form of cancer imaging, in the form of light
microscopy. Recent advances in instrumentation, computa-
tional algorithms, and imaging probes have led to new
capabilities in optical imaging of living organisms, including
small animal models and patients [29]. A variety of optical
methods have been developed that can yield in vivo images
with high contrast, and, in some cases, considerable detail,
down to the microscopic level. Methods can measure
regional biology such as vascularity and blood volume using
inherent tissue optical properties [29], or take advantage of
an ever increasing array of optical probes to image specific
molecular processes [30]. Low cost, portability, ease of use,
and wide availability of imaging probes are key advantages of
optical imaging. Its chief disadvantage is relatively limited
tissue penetration. Thus, while optical imaging has become
an essential tool for breast cancer animal research [31], its
use in patients has been more limited. While promising early
studies in breast tumor imaging point towards future clinical
application [29], optical imaging has been mostly confined
thus far to the pre-clinical setting, where it is an important tool
for breast cancer research.
Ultrasound
Ultrasound imaging works by using acoustical transducers to
send and receive ultrasound frequency energy and generate
three-dimensional images from either reflection or through-
transmission [8]. Conventional ultrasound provides high-
resolution anatomic detail, and breast ultrasound plays an
important role in breast cancer diagnosis [32]. Doppler
technology also provides information on tumor vascularity,
and with the advent of microbubble contrast agents, tumor
perfusion [33]. Recent advances in imaging technology [34]
and the development of targeted microbubble contrast
agents hold promise for molecular imaging [33]. The
portability and relatively low cost of ultrasound make it an
ideal tool for both animal and patient imaging, and the ability
to measure molecular processes will make ultrasound a
valuable tool for breast cancer research. Disadvantages
include some operator dependence in image acquisition and
interpretation, and some challenges in developing molecularly
targeted micobubble contrast agents.
Other imaging modalities such as X-ray radiography and
X-ray CT play an important role in structural imaging, but are
more limited for molecular imaging. Dynamic contrast CT can
be used to measure tissue perfusion, similar to DCE-MRI,
with the disadvantage of relatively high radiation exposure.
Available online http://breast-cancer-research.com/content/10/S1/S3Other techniques are also being investigated [35], but are at
relatively early stages of development and not discussed in
detail here.
Imaging assays: what can be measured?
Molecular and functional imaging that can measure a range of
cancer biological features have been developed and validated.
These capabilities are reviewed in this section, broadly
dividing categories of imaging assays into functional/physio-
logical properties, protein expression (with an emphasis on
tumor receptors), the tumor microenvironment, and tumor
gene expression. Both applications to animal models [36]
and patients [23] are reviewed.
Functional physiological tumor properties
Imaging is ideally suited to measuring in vivo tumor biology
related to basic physiological properties such as perfusion,
metabolism, biosynthesis, cell proliferation, and cell death. In
fact, many of these processes are difficult to assay by tissue
sampling; therefore, imaging provides a unique and quantitative
measure of these properties that can only be measured in vivo.
Tumor perfusion is one of the earliest physiological properties
to be measured, and advances in methodology have led to
increasingly quantitative approaches. The most physiologi-
cally robust and quantitative measures of tumor blood flow
use freely diffusible imaging probes, where blood flow can be
inferred from the time course of probe uptake and washout,
adapting methods developed for measuring cerebral blood
flow [37]. One example is the use of 15O-water to measure
tumor blood flow by PET, which yields measures of tumor
blood flow in ml/minute/g that have been validated against
microsphere methods [38]. Water PET imaging has been
shown to be effective in monitoring breast cancer response,
and changes in tumor perfusion with treatment measured by
water PET are predictive of survival [39]. Diffusable optical
probes may also be used for this purpose [29]. Considerable
effort has been devoted to the quantification of tumor
perfusion and tumor capillary permeability using radiographic
and MRI contrast agents [40-44]. These agents have some-
what limited permeability across capillaries; therefore, their in
vivo kinetics are dependent upon both blood flow and
capillary permeability. Increasingly sophisticated image
acquisition and analysis methods, for DCE-MRI in particular,
have led to the ability to measure regional breast cancer
perfusion and capillary permeability in both animal models
and patients [17]. Novel MRI contrast agents, including
macromolecular agents, may offer additional capabilities [45].
These methods have been applied in early trials of anti-
angiogenic therapy breast cancer and have yielded insights
into the nature of response [16]. Standardized methods for
DCE-MRI for clinical trials have been proposed [46].
Tumor perfusion imaging requires good vascular access for
prompt and reliable delivery of the imaging probe, and has
therefore been more challenging in animal models; however,
recent work using inhaled radionuclide agents hold promise
for small animal research applications [47].
Tumor metabolism has also been widely studied by imaging.
Perhaps the best known example is the measurement of
regional glucose metabolism using 18F-fluorodeoxyglucose
(FDG) PET, which is now routinely used in breast cancer
clinical practice to determine the extent of tumor spread and
assess response to treatment [5,25]. This method can also
be readily applied to animal models [48], and can yield
detailed physiological information through kinetic analysis of
dynamic images [49,50]. Other PET radiopharmaceuticals
can be used to measure other aspects of metabolism, inclu-
ding regional oxygen consumption and fatty acid metabolism
[25]. MRS has also been quite useful in measuring
metabolism through 1H spectroscopy to measure levels of
lactate and other biochemical species key in metabolism [51]
and also through phosphorous spectroscopy to measure
concentrations of adenine nucleotides as an indicator of
energy metabolism [52]. Other studies in a variety of tumors,
especially in brain tumors and prostate cancer, have shown
the ability to measure biochemical species in a variety of
metabolic pathways - for example, membrane lipids (choline)
and metabolic intermediates (citrate) - and have provided
improved diagnosis, early measures of response, and insights
into pathophysiology [53-58]. The chemical composition of
the breast, particularly its high lipid content, provides some
challenges for MRS, but recent progress in magnet field
strength, acquisition, and processing methods may offer
improved capabilities in breast cancer [59].
Aberrant cellular proliferation is a fundamental property of
cancer, including breast cancer [60]. Labeled compounds
such as 14C- or 3H-thmyidine have been an important method
for measuring cellular proliferation through sampling, dating
back over 40 years [61]. Early work used PET and 11C-
thymidine to measure tumor proliferation by imaging, and
quantitative imaging approaches were validated against in
vitro assay gold standards [62]. However, the short half-life of
11C (20 minutes) and the extensive in vivo metabolism of
thymidine limit the feasibility of this approach for both animal
and patient imaging. More recent work using thymidine
analogs labeled with 18F (half-life 109 minutes) have been
developed and undergone considerable advances in recent
years [63,64]. The most promising of these had been 18F-
fluorothymidine (FLT), with notable recent results in both
animal and patient breast cancer imaging [65-68]. FLT PET
appears especially promising for measuring the early effects
of therapy on breast cancer growth, as suggested by recent
studies by Kenny and colleagues [66]. This imaging approach
had also been validated against in vitro assay of proliferation
(reviewed in [63]) and is poised for greater use in both animal
research and human clinical trials.
Methods for imaging cell death have also been investigated,
but are at an earlier stage of development. Many of these
Breast Cancer Research    Vol 10 Suppl 1 Mankoff
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vitro, which indicates apoptotic cells through binding to
phosphotidyl serines [69]. The molecules are found only on
the inner surface of plasma membranes and, therefore,
normally not accessible to Annexin V, a peptide, for binding.
However, during apoptosis, these molecules are transiently
exposed to the extracellular space, allowing binding of
Annexin [69]. The earliest studies used 99mTc-annexin and
SPECT imaging to measure apoptosis in animal models and
patients [69,70]. More recently, methods for annexin-based
apoptosis imaging have been developed for PET, MRI, optical
imaging, and ultrasound [71]. One limitation of this approach
has been the transient nature of phosphatidyl serine exposure
during cell death, resulting in fairly limited signal for imaging
[72]. Other approaches targeted to other aspects of the
apoptotic cascade are being investigated [71]. An alternative,
but less specific approach has been to use MRI measures of
water diffusion through the extracellular space as an indirect
measure of tumor cellularity [19,73]. Increases in the diffusion
coefficient, as an indicator of a decrease in tumor cellularity,
have correlated with measures of apoptosis in animal models
[19] and response to therapy in early patient studies [20,73].
This method has the advantage of being available using
existing MRI instrumentation for both animal and patient
imaging without the need for imaging probes, but provides a
relatively indirect measure of cell death.
Several methods can also measure biosynthesis as an
indicator of tumor growth, with approaches targeted to
protein synthesis and membrane synthesis. The uptake of
labeled amino acids, such as 11C-methionine, has been
shown to correlate with tumor growth, and changes in uptake
provide an early indication of breast cancer response to
therapy [74]. This approach, however, is limited by the
complex nature of amino acid metabolism pathways, making it
difficult to measure protein synthetic rate versus amino acid
transport and metabolism [75]. Artificial amino acids have
also been tested as indicators of amino acid transport [76].
Proliferating tumor cells also engage in enhanced lipid bio-
synthesis to provide material needed for cellular membranes
[77]. This process can also be assayed through molecular
imaging using several different methods. Spurred by results in
brain tumor imaging [57], MRS studies of breast cancer have
shown increased choline pool sizes to be a feature of breast
malignancy [9,78]. Interestingly, changes in the choline
concentration measured by MRS early in treatment appear to
be a marker for early response to therapy, as early as 24 hours
after treatment with chemotherapy [22]. These exciting early
findings are now being tested in a large prospective
cooperative group trial. Lipid metabolism can also be studied
by PET using either 11C or 18F labeled choline, or 11C-acetate
[79], which enters lipid synthesis from the tricarboxylic acid
(TCA) cycle via fatty acid synthetase. Fatty acid synthetase
has been show to have increased activity and expression in
cancer and may be a target for therapy [80]. This approach
has shown considerable promise in other tumors such as
prostate cancer [81], including therapeutic response [82], but
has not been applied to the same extent in breast cancer [83].
Protein expression: tumor receptors
The ability to measure the expression of specific proteins that
are gene products associated with breast cancer has led to
important advances in breast cancer treatment. Examples
include the expression of estrogen receptors (ERs), a target for
endocrine therapy [84], and HER2, also increasingly a target of
tumor-specific treatment [85]. Molecular imaging has also been
applied to measuring specific protein expression [6,24].
Advantages of imaging include its non-invasiveness, the ability
to measure receptor expression in the entire disease burden
and thus the ability to avoid sampling error that can occur with
heterogeneous receptor expression, and the potential for serial
studies of in vivo drug effects on the target. A very practical
consideration is that imaging can assess receptor expression
at sites that are challenging to sample and assay, for example,
bone metastases, where de-calcification can make assay of
tumor gene products challenging.
Imaging protein expression, particularly tumor receptors,
poses some unique challenges. For receptors, imaging
results can be quite sensitive to the molecular quantity of the
imaging probe needed to generate the image. Most receptors
have high affinity for their ligands and are active at micromolar
or nanomolar concentrations of the ligand. Even small molar
quantities of the imaging agent may saturate the receptor and
limit the ability to visualize receptor expression [86,87]. For
this reason, molecular imaging of tumor receptors has been
most successful to date with radionuclide imaging, PET and
SPECT, where it is possible to generate images with nano-
molar or picomolar amounts of the imaging probe. For larger
molecules, like peptides and monoclonal antibodies, other
labels suitable for optical, MR, and ultrasound imaging are
possible [6]; however, for small-molecule receptor imaging
agents, such as labeled steroids for steroid receptors, radio-
nuclide imaging appears to be the only feasible approach.
The most work to date in this area of breast cancer research
has been done for steroid receptors [6,88]. Considerable
efforts have gone into the development of radiopharma-
ceuticals for ER imaging, as reviewed in [88-90]. Although a
variety of ER imaging agents have been tested, and continue
to be developed and tested, the most successful ER imaging
radiopharmaceutical to date is 16 alpha-[18F]-fluoro-17 beta-
estradiol (FES) [87,91]. FES has binding characteristics
similar to estradiol for both the ER and the transport protein
SHBG [92,93]. It can be synthesized with sufficient specific
activity that high-quality patient images can be made with
injections of less than 5 μg of FES [94]. Regional estrogen
binding is readily quantified by FES PET, and FES uptake has
been validated as a measure of ER expression in breast
tumors against ER expression assay of tissue samples by
radioligand binding [95] and immunohistochemistry [96]. FES
Available online http://breast-cancer-research.com/content/10/S1/S3
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metastatic breast cancer [97]. It can identify heterogeneous
ER expression, for example, loss of ER expression in meta-
stases arising from ER-expressing primary tumors [94,97].
The level of FES uptake has been shown to be predictive of
response to endocrine therapy [94,98], including heavily
pre-treated patients (Figure 1). Serial FES PET can also
measure the pharmacodynamic effect of drugs on estradiol
binding to the ER [98,99], yielding insights into determinants
of drug efficacy.
While PET ER imaging had been successful, efforts to image
progesterone receptor (PR) have been less successful
[100,101]. In a study of the PR imaging agent 21-[18F]fluoro-
16 alpha-ethyl-19-norprogesterone, uptake was seen in some
tumors, but the level of uptake did not correlate with the level
of PR expression. This may be in large part due to the
relatively low affinity of progestins for the PR, with binding
affinities that are orders of magnitude lower than those of
androgens and androgen receptors and estrogens and ERs
[101]. As such, relatively high non-specific binding compared
to specific binding of imaging probes may limit their utility for
PR imaging. Later studies also showed that the radiopharma-
ceutical tested was rapidly metabolized in human to a
metabolite with poor receptor binding [102], a finding that
was not predicted by pre-clinical models. Efforts to develop
effective PR imaging agents continue [103].
HER2 (ErbB2) expression in breast cancer has become an
important indicator of prognosis and an increasingly impor-
tant target for therapy [104]. Recent efforts have focused on
imaging HER2 expression in breast cancer. The most
success and largest number of studies to date used imaging
probes based upon immune recognition to image HER2
expression. Specific imaging probes based on radiolabeled
antibodies or fragments [105-109], or novel constructs such
as affibodies [110,111], have shown success in early studies.
Studies using a 68Ga-labeled F(ab’)2 fragment of trastuzumab
by Smith-Jones and colleagues [112,113] demonstrated the
feasibility of measuring regional HER2 expression in murine
animal models. The imaging results nicely demonstrated
alterations in HER2 expression accompanying experimental
therapy using HSP90-directed agents (geldamycin analogs)
to disrupt protein chaperoning and reduce HER2 expression
[112,113]. Studies using 131I- or 111In-labeled trastuzumab
have demonstrated the ability to image tumor expression of
HER2 and tumor and normal tissue accumulation of
trastuzumab [108,114,115], although there has been some
controversy about the significance of uptake in normal tissues
prone to trastuzumab toxicity, such as the heart [108,115].
Promising early patient studies have also been presented for
89Zr-labeled trastuzumab [116].
For imaging using larger molecules like monoclonal anti-
bodies and fragments, as in the case of HER2 imaging, an
even wider range of probes (and therefore imaging
modalities) may be possible, including optical, ultrasound,
and MR-based probes [117-122]. Koyama [123] demon-
strated specific fluorescence imaging of HER2-expressing
lung metastasis in an animal model. Others have used near-
infrared imaging of HER2 expression in vitro using gold
nanoshell bioconjugates [124] and fluorochrome labeling
[125]. Pre-clinical studies using specific antibodies conju-
gated to gadolinium or magnetic nanoparticles demonstrated
the feasibility of MRI antibody imaging in cells [126] and
animal models [118]. Early studies of nanoparticle-based
ultrasound probes conjugated to HER2-specific antibodies
have demonstrated the feasibility of this approach in early in
vitro studies and simulated in vivo studies [119,127]. The
ability to image with multiple modalities is particularly helpful
for translating research from the pre-clinical to clinical setting.
For example, optical imaging is extremely valuable for small-
animal studies, but has limited utility in patients due to poor
tissue penetration for imaging deeper structures. The ability
to translate optical imaging findings into PET or MRI imaging
in patients, seen in early work for HER2 imaging, holds great
promise for facilitating translational research.
Tumor microenvironment
Molecular imaging provides a unique opportunity to image the
tumor microenvironment, which is challenging by more
Breast Cancer Research    Vol 10 Suppl 1 Mankoff
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Figure 1
Imaging examples: pre-treatment (Pre-Rx) 16 alpha-[18F]-fluoro-
17 beta-estradiol positron emission tomography (FES PET; left) and
18F-fluorodeoxyglucose (FDG) PET (middle) scans and follow-up FDG
PET post-therapy (Post-Rx; right) are shown. Dashed arrows show
normal liver FES uptake. (a) This patient has bone metastasis with
robust FES and FDG uptake, and had response at 3 months. (b) This
patient has bone metastasis (solid arrow) without FES but with FDG
uptake; progressive disease at 6 months. (Reproduced from [94].)invasive means. Tumor hypoxia, an important factor mediating
cancer aggressiveness and therapeutic resistance [128,129],
has been widely studied by imaging, with some recent
studies in breast cancer [130]. Most work has been done
using PET imaging and the agent 18F-fluoromisonidazole
(FMISO) (Figure 2); however, other PET hypoxia probes have
been developed and tested [38]. Other hypoxia imaging
methods based upon MRI and optical approaches are at an
earlier stage of development, but appear promising [131,132].
Tumor vasculature plays a key role in tumor growth and
metastasis, and is also important in the delivery of systemic
therapeutic agents. Imaging of tumor vasculature and the
delivery of nutrients and drugs has also been an area of
interest. Tumor perfusion and capillary transport provide an
indirect measure of tumor vasculature and can be imaged by
DCE-MRI and PET, which have been effective in measuring
tumor response in early studies [16,38,39]. In addition,
targeted imaging probes can non-invasively and specifically
assess tumor neo-vasculature. PET probes based upon
specific labeled peptides that bind to integrins expressed in
neovessels have been studied in animals and tested in
humans [133,134]. MRI probes have been developed and
are at an earlier stage of testing [40]. Such agents may be
especially helpful for therapies directed at tumor neo-
vasculature, such as bevacizumab.
Imaging methods to measure nutrient and drug transport have
also been developed and tested. For example, the SPECT
agent  99mTc-sestamibi, developed for myocardial perfusion
imaging, has been shown to be a substrate for the drug efflux
transporter P-glycoprotein [135]. Studies in the setting of pre-
surgical chemotherapy showed that the uptake and retention
of  99mTc-sestamibi was predictive of response to chemo-
therapeutic agents that are substrates for P-glycoprotein, such
as epirubicin [136]. Somewhat more specific and quantitative
probes of P-glycoprotein transport have been developed for
PET imaging [137-139]. Macromolecular MRI contrast agents
are undergoing testing in patients [140] and may be useful for
measuring the delivery of therapeutic agents, such as
trastuzumab, that are large molecules where capillary and
interstitial transport may pose significant barriers.
Reporter gene imaging and cell labeling
Advances in cancer biology have led to an increasing array of
approaches to breast cancer therapy, including immuno-
therapy and gene therapy. These advances in turn lead to the
need for increasingly sophisticated approaches for imaging to
monitor these treatments. An increasing body of work in
molecular imaging has therefore been devoted to imaging
approaches capable of imaging gene expression and cellular
trafficking and survival in vivo [12,82].
Paralleling work done in reporter systems for cell culture,
imaging reporter systems have been developed and are
increasingly used in animal model research [141-143].
Reporter imaging can use optical approaches, with reporter
genes expressing optically detectable molecules such as
green fluorescent protein and firefly luciferase. Optical
approaches provide inexpensive, readily available methods for
imaging reporter gene expression, and are widely used in
current research [144]. Radionuclide methods have also
been developed and widely tested in animal models [143].
The most popular approach has been based upon the use of
viral thymidine kinase as a reporter gene, combined with
labeled probes that are specific substrates for phos-
phorylation by viral thymidine kinase [145,146]. This results in
probe trapping and high-contrast, readily quantifiable images
[147]. A variety of other radionuclide reporter systems have
been used, including the NaI symporter and radioiodine,
receptor expression (for example, dopamine) and receptor
binding ligands, and alternative metabolic substrates
[148,149]. Some progress has also been made in MRI
reporter systems [150,151]; however, this work is at an
earlier stage than optical and PET approaches.
The development of therapeutic approaches mediated by
specific cells - for example, immunotherapy - has generated
increasing interest in cell labeling and imaging. Cell labeling
Available online http://breast-cancer-research.com/content/10/S1/S3
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Figure 2
Breast tumor hypoxia as a predictor of drug resistance. A patient with a
large, right breast tumor underwent 18F-fluorodeoxyglucose (FDG) and
18F-fluoromisonidazole (FMISO) positron emission tomography (PET)
pre-therapy (Pre-Rx; top and middle) and after approximately ten
weeks of chemotherapy (Post-Rx; bottom). Images are thick sagittal
images, similar to medial-lateral oblique (MLO) mammography views.
The pre-therapy FDG study showed uniformly high FDG uptake
throughout the tumor. FMISO PET showed uptake suggestive of tumor
hypoxia, but only close to the center of the tumor (arrow). Post-therapy
images show a dramatic reduction in the extent and intensity of FDG
uptake with residual activity in the part of the tumor that had FMISO
uptake pre-therapy. Residual viable tumor was found at surgery.
Marrow uptake of FDG was also seen post-therapy (dashed arrow)
because of granulocyte colony-stimulating factor administered for
marrow support as part of the treatment. (Reproduced from [158].)can be done using non-specific probes, such as 111In-oxine
and non-targeted iron oxide particles for use in SPECT and
MRI, respectively [152]; however, this approach often
requires isolation of the cells to assure that only the desired
cells are imaged. In cell therapy where molecular
manipulation is possible, cells engineered with reporter
systems can also be used to provide specific cell labeling
that does not require isolation of cells and that remains with
the cells through subsequent generations, unlike most non-
specific methods [153]. For immunotherapy, the generation
of reporter systems that do not themselves engender an
immune response is a challenge and represents an active
area of research [154].
Summary and future directions
Advances in molecular biology create new opportunities for
understanding and treating breast cancer, and also create
new needs for increasingly sophisticated and quantitative
assays. Advances in both technology and molecular biology
have led to the capability for molecular imaging, a method for
non-invasive and regional assay of in vivo tumor biology.
While some molecular imaging methods, most notably
SPECT and PET, have begun to be used in patients, many
molecular imaging approaches have, as yet, undergone only
early testing at a pre-clinical stage. Some methods, such as
optical reporter gene imaging, have already become an
important part of basic research in animal models. Other
approaches, such as PET imaging of tumor receptor
expression, look very promising in early patient studies, but
have yet to make it to larger clinical trials or clinical practice.
Only a relatively few approaches, such as FDG PET, have
made their way into clinical practice.
Molecular imaging offers a very powerful tool for translating
basic science into clinical benefit. This can happen in several
ways. Demonstration that molecular pathways discovered in
animal models have relevance to human breast cancer is a
critical aspect of breast cancer translational research. Mole-
cular imaging offers a way to assess and quantify pathways in
both animal models and patients in order to verify that the
pathways behave similarly in both cases. In addition, molecular
imaging used to guide drug development and pre-clinical
testing can be applied to early clinical studies to provide
proof-of-concept, early evidence of efficacy, and a pharma-
codynamic measure by which to optimize dosing [155].
There are a number of potential hurdles to translating
molecular imaging methods from animals to humans. Some
approaches that work well in animals - for example, optical
imaging - may not be applicable to patients. Multi-modality
imaging approaches - for example, combined optical/MR/PET
reporters - may be very helpful in this regard. There may be
significant regulatory hurdles to the use of some imaging
probes in patients. Recent efforts in collaborations between
the NCI, FDA, and other organizations show promise in
helping to facilitate clinical trials of new probes [156].
Echoing trends in molecular breast cancer therapy, clinical
trials of molecular imaging may need new approaches to
clinical study design, using measures such as prognosis or
response as endpoints, rather than sensitivity and specificity
for tumor detection [4]. Cooperative groups and scientific
organizations have recognized this need and are beginning to
address it through a variety of approaches, including multi-
center trials [157]. While somewhat daunting, these hurdles
are clearly surmountable by close collaboration between
breast cancer biologists, clinicians, and imagers. Early results
suggest that molecular imaging will play an important role in
translational breast cancer research and the care of breast
cancer patients and strongly support ongoing efforts in this
area of research.
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